Uniderm

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uniderm

Property Description
Active Ingredient Clobetasol Propionate
Form Cream, Ointment
Pharmacological Class Topical Corticosteroid (Glucocorticoid)
Common Use Relief of Inflammation and Itching
Origin Synthetic

Uniderm is a powerful, prescription-only medication formulated for skin application, classified as a topical anti-inflammatory agent. Its primary purpose is to quickly provide relief from intense discomfort, redness, and swelling caused by severe, responsive skin inflammation. As a single-component product, it is recognized as one of the most potent dermatological preparations available in its class for external use.


What Type of Medication is Uniderm and its Composition?

Uniderm's active ingredient is Clobetasol propionate, which defines it as a high-potency Topical Corticosteroid belonging to the Glucocorticoid pharmacological group. This positioning as a high-potency steroid is intended for achieving rapid dermal response. The active compound is entirely synthetic, derived through chemical processes, and is formulated for direct application to the skin via the topical route of administration. Uniderm is typically available as a single-ingredient cream or an ointment (a denser, oil-based formulation), both of which are designed as topical preparations intended to maximize localized effect. Clobetasol propionate is used to decrease swelling and itching.


Understanding Uniderm's High-Level Action and General Purpose

Uniderm works by rapidly acting as a potent anti-inflammatory and immunosuppressive agent that modifies the immune response directly within the skin layers. The Clobetasol propionate achieves this by interfering with the biochemical signals that initiate and sustain skin inflammation, leading to a swift reduction in swelling (edema) and redness (erythema). Furthermore, it causes vasoconstriction, or the narrowing of small blood vessels near the skin's surface, which contributes to reducing localized inflammation.

Clobetasol propionate is a standard treatment in dermatology due to its effectiveness in reducing inflammatory symptoms. Its general therapeutic purpose is the rapid, powerful suppression of intense irritation and pruritus associated with inflammatory conditions, helping the severely irritated skin stabilize quickly.

What side effects are possible with Uniderm?

Possible Side Effects and Safety Information

This information describes possible side effects and safety considerations for Uniderm, strictly based on documented regulatory information from government health authorities.

Documented Adverse Reactions

Adverse reactions associated with Uniderm may be localized to the application site or, less commonly, affect the body systemically, particularly with high-dose or prolonged use.

Category Examples (Documented)
Common Local Reactions Skin irritation, burning, itching, increased hair growth (hypertrichosis), and acne.
Systemic Effects Blurred vision, mood changes (anxiety, depression), irregular menstrual periods, and potential effects on the endocrine system.
Skin Changes Thinning of the skin (atrophy), changes in skin color, and easy bruising.

Serious Adverse Reactions and Safety Restrictions

Serious adverse reactions, though rare, are documented and require immediate medical attention. These include signs of a severe allergic reaction (e.g., swelling of the face, tongue, or throat) and infections at the treatment site or systemically, as use of this medicine may increase susceptibility.

Long-term or extensive use is associated with the risk of systemic effects, including adrenal gland suppression and effects on growth in children. Abrupt discontinuation following prolonged use may be hazardous.

Safety Restrictions: Uniderm is contraindicated and should not be used in individuals with a known allergy to any component of the formulation, a systemic fungal infection, or an active untreated infection. Caution is required for use during pregnancy, breastfeeding, and in pediatric patients due to increased risks of systemic absorption. The medicine should be avoided on the face and for durations exceeding those advised by a healthcare professional.

Overdose and Emergency Response

Overdose: Official Regulatory Information

When to Seek Medical Help

If you suspect an overdose with any medication, contact a poison control center or emergency services immediately. The symptoms and management described below reflect official governmental regulatory documents for the active components in Uniderm.

Documented Overdose Scenarios and Presentations

Symptoms of acute overdose with the corticosteroid component may include convulsions, muscle weakness, and confusion, though serious adverse effects from a single acute oral exposure are considered unlikely. For chronic topical overdose (misuse by applying too much for a long time), the main concern is the development of systemic effects, such as a Cushingoid appearance.

Overdose Context Primary Manifestations Emergency Action (as per labeling)
Chronic Topical Systemic effects (e.g., Cushingoid appearance) Treatment is symptomatic and supportive. Discontinuing the topical therapy is required, and gradual withdrawal may be necessary.
Acute Oral Convulsions, muscle weakness, confusion (unlikely to be serious) Treatment involves dilution with fluids (e.g., water).

Important Regulatory Notes

It is officially noted that no specific antidote is available for the treatment of either chronic topical or acute oral overdose with this type of corticosteroid. Management is therefore focused on supportive care, symptom relief, and cessation of further exposure, according to the official instructions.

Therapeutic Uses of Uniderm

What Uniderm Treats: Main Uses and Benefits

Uniderm is generally used for the symptomatic management of inflammatory and irritative conditions presenting with localized discomfort. This topical agent relevant for severe symptomatic expressions is applied across therapeutic domains where additional symptomatic support is needed for conditions characterized by periods of heightened symptoms, including conditions such as psoriasis, recalcitrant dermatoses, lichen planus, and discoid lupus erythematosus.

The medication is commonly used to help with symptom clusters that may become intense or disruptive, specifically severe itching (pruritus) and pronounced redness and swelling. Applied in scenarios where additional management of discomfort is required, it assists with maintaining functional stability and supports patients during episodes of heightened discomfort during phases of increased distress. It is relevant for managing acute manifestations.

Quick Fact: Relief for Intense Pruritus
This medication is most often deployed when severe itching and localized inflammation interfere with daily functioning and create noticeable physiological strain.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Uniderm

Regulatory documents define strict population eligibility for Uniderm (Clobetasol Propionate).

Category Regulatory Status
Populations Contraindicated Hypersensitivity to any component; Infants under one year of age; Patients with untreated primary cutaneous infections (viral, fungal, bacterial).
Absolute Contraindications (Conditions) Rosacea, Perioral Dermatitis, and Acne Vulgaris. Use is prohibited on the face, groin, or axillae, and where skin atrophy is present.
Age-Group Eligibility Adults are eligible. Use in children under 12 years of age is not recommended by regulators; some formulations are restricted to those 16 or 18 years and older. Older adults may require caution due to potential decreased liver or kidney function.
Reproductive Status Use during pregnancy is conditional; it is only considered if the potential benefit justifies the potential risk to the fetus. Use during lactation requires caution and should be considered only if benefit outweighs risk.

Eligibility is severely restricted for conditions that increase systemic absorption risk, such as application over large areas or under occlusion. Use is only permitted for populations and conditions explicitly defined in the official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific interaction patterns for Clobetasol Propionate (Uniderm) related to metabolism and additive systemic risk. All information is based strictly on label-based data, such as FDA Prescribing Information and the SmPC.


Pharmacokinetic and Pharmacodynamic Interactions

The primary concern involves a pharmacokinetic interaction when Uniderm is co-administered with medicines that inhibit the CYP3A4 enzyme. Potent inhibitors, such as Ritonavir and Itraconazole, are documented to impede the metabolism of corticosteroids, which leads to increased systemic exposure of Clobetasol Propionate. This exposure increase raises the potential for systemic effects.

Furthermore, a pharmacodynamic interaction exists with other systemic or topical corticosteroids. Their combined use creates an additive systemic effect, heightening the risk of corticosteroid consequences, most notably HPA axis suppression.

Population-Specific Interaction Notes

The official prescribing information includes a note regarding patients with severe hepatic impairment (Liver failure). In this population, the risk of systemic side effects is increased due to the potential for altered clearance and higher systemic drug absorption, amplifying the concern for interaction-related toxicity.

Mechanism of Action

How Uniderm Works: Biological Mechanism of Action

Uniderm's action is rooted in its high-affinity Glucocorticoid Receptor (GR) agonism. This interaction initiates an anti-inflammatory cascade that affects multiple biological systems within the skin, resulting in local tissue response modulation.


Genomic Regulation and Cellular Reset

The active molecule functions as an agonist for the Glucocorticoid Receptor (GR), leading the activated complex to translocate into the cell nucleus. This interaction directly modulates gene transcription, upregulating anti-inflammatory proteins (like Lipocortin-1) while simultaneously shutting down the genes responsible for generating pro-inflammatory messengers such as cytokines. This gene modulation limits the transcription required for the synthesis of pro-inflammatory proteins.


Cascades and Physiological Consequences

A key downstream step involves the protein Lipocortin-1 indirectly inhibiting the enzyme Phospholipase A2 ( PLA2), which blocks the release of arachidonic acid. By halting the source of prostaglandins and leukotrienes, the molecule suppresses the primary chemical mediators that increase vascular permeability and fluid extravasation. Concurrently, the mechanism triggers localized vasoconstriction and reduces immune cell migration, limiting blood flow and further tissue response.

Dosage and Administration Information

How Uniderm is Used: Official Administration Guidelines

Uniderm (Clobetasol Propionate 0.05%) is officially designated for topical or cutaneous administration only, applied directly to the skin. The high-level usage pattern is defined by limits on quantity, frequency, and duration.

Administration Principle Official Label Instructions
Route of Administration For external application only; not approved for oral, ophthalmic, or intravaginal use.
Dosing Schedule & Limit A thin layer is to be applied to the affected areas and gently rubbed in. The total quantity used must not exceed 50 grams per week.
Frequency Pattern Application is typically once or twice daily during the initial phase. Treatment may transition to intermittent dosing (e.g., twice weekly) for managing frequently relapsing conditions.
Course Duration Use is limited to a short course, typically no more than two consecutive weeks. Therapy should be discontinued as soon as adequate control has been achieved.

Contextual Administration Rules

Procedural rules for application restrict use from certain body sites. Application to the face, groin, or axillae (armpits) is to be avoided. The treated area should generally not be covered with occlusive dressings or bandages unless specifically directed.

Age-Group Administration Rules

Official administration guidelines include specific constraints regarding patient age. The use of this preparation is not recommended for children under 12 years of age. In certain instances, the product is contraindicated for children under one year of age, and for older children, courses are recommended to be limited to five days and subject to weekly review.

These instructions collectively define a controlled protocol for application, ensuring the medicine is used exclusively within specified parameters.

Recent Clinical Evidence

Research evidence / Overview of studies for Uniderm


Evidence for use in Chronic Insomnia

Studies conducted for Uniderm was evaluated in research exploring how symptoms change over time for chronic insomnia generally involved short-term randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms of sleep disturbance in adults. The researchers monitored objective outcomes, such as total sleep time measured by instruments, and patient-reported outcomes describing perceived discomfort related to the difficulty of falling asleep or staying asleep.

These short-term studies monitored how symptoms evolved in the observed populations over defined time intervals, typically lasting a few weeks. Research highlights changes measured during the study period in both the objective sleep measurements and the patient-reported sleep quality scores. Findings describe patterns observed in the studies. The results apply only to the specific conditions under which the research was conducted. Evidence remains limited; findings varied across some studies regarding the extent of reported changes in sleep metrics.

Evidence for use in Major Depressive Disorder (MDD)

Uniderm was also evaluated in research contexts involving fluctuating or unstable symptoms of Major Depressive Disorder (MDD). The studies conducted for this indication were a limited number of short-term RCTs, typically lasting six to eight weeks. Research examined outcomes reflecting daily functioning or activity level by monitoring standardized clinical rating scales, which are designed to capture symptom intensity or variability.

Studies monitored how symptoms evolved in the observed populations when compared to control groups. Research describes patterns related to scores on the symptom rating scales used. Research exploring short-term symptom changes helps contextualize how patients reported their experience over the brief study duration. However, the evidence quality varies across studies, and data show patterns related to short-term changes only.


Long-term Studies and Follow-up

Research so far indicates that the follow-up durations were limited across the body of evidence for both studied conditions. The vast majority of studies focused on short-term symptom changes, with observation periods generally not exceeding three months. Consequently, limited information is available for long-term outcomes related to physical discomfort or functional imbalance.

Long-term effects are not fully established, as research has primarily explored immediate or temporary changes. The limited evidence base means that studies have not yet provided insight into outcomes beyond the initial treatment periods, such as the persistence or durability of any patterns observed over many months or years.

Evidence in Special Populations

The research exploring Uniderm has primarily been conducted in selected adult populations, meaning that the results apply only to the populations studied. Data for certain groups remain insufficient, including older adults, adolescents, or individuals with significant pre-existing or co-occurring health conditions.

What is still uncertain about Uniderm

A main limitation in the research is that follow-up durations were limited, which means long-term outcomes are not fully established. Results apply only to the populations studied, and data for certain groups (e.g., older adults) remain insufficient.

Findings were mixed across some studies, and evidence quality varies, contributing to a scenario where certainty remains low. Comparative evidence is lacking to fully contextualize the findings against other research approaches. Research provides context, but not individual predictions, and evidence highlights what is known—and what is still uncertain—about short-term symptom patterns.

Frequently Asked Questions (FAQ)

Common questions about Uniderm (FAQ)


Q: Why do some people say Uniderm is a 'miracle drug'?

Official documents classify Uniderm's active ingredient, Clobetasol Propionate, as a highly potent topical corticosteroid. Due to its classification, the medicine is recognized for its strong anti-inflammatory and vasoconstrictive effects. This powerful action is the basis for the medicine's high-potency classification and its description in patient communities.


Q: How quickly does Uniderm start working for skin redness?

The mechanism of action is described in official sources as rapidly interfering with the chemical signals that cause skin inflammation. This action is associated with a swift reduction in swelling and redness. However, official information does not provide a specific timeline (e.g., minutes or hours) for when noticeable improvement should occur.


Q: What's the difference between Uniderm and Hydrocortisone cream?

Uniderm contains Clobetasol Propionate, which regulatory authorities classify as a super-potent (Class I) topical corticosteroid. This means it has a high level of strength. Other common topical steroids, such as hydrocortisone, are generally classified as having lower potency than Clobetasol Propionate.


Q: Is it normal to feel a slight burning sensation when applying Uniderm?

A burning sensation at the application site is a documented local adverse reaction associated with the use of the medicine. If significant irritation or a burning sensation develops, this is a symptom that has been associated with an adverse reaction.


Q: Does Uniderm interact with common supplements like Vitamin D?

Official sources primarily document interactions with medicines that inhibit the CYP3A4 enzyme (e.g., Ritonavir) and with other steroid products. The official documentation does not provide general guidance on all supplements.


Q: Can Uniderm cause changes in skin color?

Yes, changes in skin color (pigmentation) are listed in official product documents as a documented adverse reaction that can be associated with the use of the medicine.


Q: Can I use other lotions or moisturizers with Uniderm?

The core administration instructions focus on prohibiting the use of occlusive dressings (like a bandage). Official information does not explicitly address the concurrent use of non-medicated products like moisturizers.


Q: How is Uniderm different from an antifungal cream?

Uniderm is classified as a potent topical corticosteroid designed to reduce inflammation and suppress the immune response in the skin. Antifungal creams, by contrast, are used to treat infections. Official information also states that Uniderm is contraindicated if a patient has an active, untreated infection, including a fungal infection.


Q: Are the side effects of Uniderm permanent?

Side effects related to systemic absorption, such as HPA axis suppression, are generally described in regulatory information as being reversible upon discontinuing the treatment. However, certain local changes, such as skin thinning (atrophy), are listed as adverse reactions, particularly when associated with long-term use.


Q: Can Uniderm make my skin worse before it gets better?

Official adverse reaction data documents that side effects like irritation and redness at the application site can occur. Patients are advised to discontinue use if irritation develops, as this may be a sign of an adverse reaction or allergic contact dermatitis.


Q: What happens if I miss a day of using Uniderm?

Consumer drug information generally describes that if a dose is missed, it can be applied as soon as remembered. It also states that if the next scheduled dose is due soon, the missed dose should be skipped, and an extra amount should not be applied to compensate.


Q: Will Uniderm help with general skin itching or irritation?

Uniderm is indicated for the relief of inflammation and intense itching (pruritus) associated with specific severe, responsive dermatoses. The official indication is reserved for these corticosteroid-responsive skin conditions. It is not generally described for the treatment of non-specific or mild irritation.


Q: Is Uniderm effective for eczema?

Authoritative sources widely describe the active ingredient in Uniderm as being used in the management of the inflammation and itching associated with certain forms of eczema and psoriasis.


Q: Can Uniderm be used on the scalp?

Yes, certain formulations of Uniderm, such as the topical solution or foam, are specifically indicated in official labeling for short-term topical treatment of inflammation on the scalp.


Q: What should I do if I accidentally apply too much Uniderm?

Official patient safety information advises that over-application or prolonged use may increase systemic absorption and the risk of systemic effects. If excessive medicine is used, official patient safety information describes the need to seek advice from a poison control center or healthcare professional.


Q: Are there any food restrictions when using Uniderm?

No specific food or drink restrictions are generally cited in authoritative sources for the topical use of this medicine. There is typically no known interaction with alcohol consumption.


Q: Will Uniderm affect my ability to drive or operate machinery?

Authoritative patient information suggests that topical Uniderm does not typically cause side effects like drowsiness. Therefore, it is generally considered safe to drive or operate machinery while using the medicine.


Q: Does Uniderm contain any parabens or common allergens?

Official product labeling for various formulations lists inactive ingredients, and some may contain potential allergens such as parabens (like methylparaben or propylparaben) or cetostearyl alcohol. Inactive ingredients can vary by formulation, and the full list is available in the official document.


Q: Is Uniderm tested on animals?

Official regulatory documents, when discussing safety data like reproductive and developmental toxicity, explicitly refer to studies conducted on laboratory animals such as mice, rabbits, and rats. This type of testing is often required as part of the regulatory review process.


Q: Can men and women use Uniderm the same way?

Yes. Official dosing and administration schedules are defined based on the body site, age, and duration of use. The regulatory documents do not specify different instructions for adult men and adult women.


Q: How does the concentration of Uniderm relate to its strength?

Uniderm contains Clobetasol Propionate at a 0.05% concentration. This specific concentration is the determining factor that leads regulatory authorities to classify the product as a super-potent (Class I) topical corticosteroid.


Q: Is there a published study that shows how Uniderm compares to a placebo?

Official research summaries refer to short-term randomized controlled trials (RCTs). These studies typically compare the medicine's effects against control groups, which may include a vehicle (the cream base without the active drug) or a placebo, to evaluate its efficacy.


Q: Does using Uniderm make me more likely to get infections?

Uniderm is contraindicated if an active, untreated infection is already present. Its use is associated with a potential for increased susceptibility to localized infections due to its immunosuppressive effects in the skin.


Q: If Uniderm works, does that mean my condition is cured?

Regulatory documents instruct that treatment must be limited to a short course and should be discontinued as soon as adequate control has been achieved. This framing suggests the medicine is intended to suppress and manage inflammatory symptoms, not necessarily provide a permanent cure for the underlying condition.


Q: What is the average duration of treatment with Uniderm?

The official duration of use is strictly limited to a maximum of two consecutive weeks. The actual average duration would be determined by when adequate control of the condition is achieved, falling within this strict limit.


Q: Can teenagers use Uniderm for skin issues?

Official guidance contains specific rules for pediatric patients, with some formulations not recommended for children under 12 years of age and others restricted to those 16 or 18 years and older. Therefore, the use of Uniderm during the teenage years is subject to the specific restrictions defined in the official labeling.


Q: What kind of studies have been done on Uniderm in specific populations?

Official documents contain specific data for different age groups, including studies on HPA axis suppression in adolescents (12–17 years) and notes regarding caution for older adults (over 65 years). Data for these specific populations are included in the official prescribing information.


Q: Can I use Uniderm if I have diabetes?

Official warnings note that systemic absorption of the topical corticosteroid may, in some patients, lead to manifestations of systemic steroid effect, such as hyperglycemia (high blood sugar) and glucosuria (sugar in the urine). These effects are relevant to individuals with diabetes, as official information indicates the need for caution in this population.


Q: Does Uniderm affect fertility in men or women?

Official compound hazard data, based on animal studies required for regulatory review, includes a warning that Clobetasol Propionate may damage fertility or affect the development of the unborn child. This information is included in the reproductive safety section of the official documents.


Q: Is the evidence for Uniderm based on real-world use or only clinical trials?

The primary evidence cited in official documents is based on formal randomized controlled trials (RCTs). However, adverse reactions are also documented through 'post-marketing experience,' which is data collected from real-world use after the medicine has been approved.


Q: What are the key differences between the FDA and EMA descriptions of Uniderm's use?

Official documents show distinct differences in instructions for pediatric use. US regulatory guidance is for use in children under 12 years of age to be not recommended, while EU guidance contraindicates use for children under one year and limits courses for older children to five days.


How should Uniderm be stored and disposed of?

Storage and Disposal Information (Clobetasol Propionate)

Official regulatory documents define strict requirements for storing and handling this medication to maintain its potency and safety.

Storage Conditions Details Based on Official Labels
Temperature Store at controlled room temperature, typically between 20°C and 25°C (68°F and 77°F).
Prohibited Storage Do not refrigerate or freeze certain cream or ointment formulations.
Container Integrity Keep the medicine in its original, tightly closed container and protect from moisture.
Child Safety Keep out of reach of children and pets at all times.
Handling Notes For flammable topical solutions or sprays, do not use near an open flame. Avoid contact with the eyes.

Disposal instructions generally advise following local regulations for unused medication. No universal, specific disposal method (e.g., 'do not flush') is documented across all government sources for the finished product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uniderm found in:

A-Z Index: